Evidence mapPaperPMID 41885295Full record

ReviewJournal of Parkinson's disease2026

Harnessing artificial intelligence: Revolutionizing clinical care for Parkinson's disease.

William J Marks

Abstract readReview
In one paragraph

Review in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

William J MarksDepartment of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-3692-2480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the use of artificial intelligence (AI) in healthcare becomes more pervasive, its application in the clinical care for those with Parkinson's disease (PD) presents exciting opportunities to improve the timeliness and accuracy of diagnosis and to optimize treatment. Perhaps more than many other neurological conditions, PD lends itself to the creation of rich data from which AI can surface actionable insights that hold the potential to revolutionize PD care in a personalized manner. For direct clinical care, AI has the potential to contribute to initial diagnosis, disease subtyping, symptom identification and severity assessment, progression monitoring, and treatment management. With patients and clinicians informing AI and contributing to its methods of deployment, an enormous opportunity exists to open up access to expert-level care to many more people.

Indexed as

advanced therapiesbiomarkersmobilitymovement analysistechnology

Identifiers

PMID41885295
PMCPMC13438411

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.